Overview

Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients

Status:
Unknown status

Trial end date:
2020-09-01

Target enrollment:

Participant gender:

Summary

Obesity is a complex metabolic state at which many pathophysiological pathways seem to interfere, like imbalance of autonomic nervous system, as well as renin-angiotensin-aldosterone system (RAAS) activation. Latest studies have shown that the increase of peripheral fat in obese patients, alongside with the increase of P-450 aromatase leads to hyper-aldosteronism, which results to increased sodium intake and rise of blood pressure. The present study aims to investigate the potential superiority of an aldosterone antagonist based therapy (eplerenone) over the renin-angiotensin antagonists (ARBs) (valsartan) based therapy in hypertensive obese patients regarding reduction of blood pressure (office, home and ambulatory) over a 24-week period.

Phase:

Phase 4

Details

Lead Sponsor:

Hippocration General Hospital

Treatments:

Amlodipine
Eplerenone
Indapamide
Mineralocorticoid Receptor Antagonists
Mineralocorticoids
Spironolactone
Valsartan